Open AccessImmune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Author(s) -
ChingYuan Chang,
Haesuk Park,
Daniel C. Malone,
Ching-Yu Wang,
Debbie L. Wilson,
Yu-Min Yeh,
Sascha van Boemmel-Wegmann,
Wei-Hsuan Lo-Ciganic
Publication year - 2020
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2020.1611
Subject(s) - medicine , nivolumab , ipilimumab , pembrolizumab , adverse effect , oncology , randomized controlled trial , odds ratio , cancer , immunotherapy
This systematic review and meta-analysis evaluates the immune checkpoint inhibitor regimens used along with the incidence of adverse events reported in randomized clinical trials for treatment of advanced melanoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom